Status:
COMPLETED
Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Neovascular Age-related Macular Degeneration
Eligibility:
All Genders
50+ years
Brief Summary
The goal of this retrospective single-center chat review is to establish the efficacy and safety of a single dose of intravitreal faricimab (Vabysmo®) injection in patients with neovascular age-relate...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Presence of neovascular age-related macular degeneration (AMD) in the study eye
- \>50 years of age
- Previous intravitreal anti-VEGF treatment with aflibercept (Eylea®) or with aflibercept and ranibizumab (Lucentis®) in the study eye
- Minimum of 6 monthly aflibercept injections
- Persisting intraretinal or subretinal fluid or both, despite at least 3 consecutive monthly aflibercept injections in the study eye before switching to faricimab
- Exclusion criteria
- Neovascular conditions other than AMD (e.g., choroidal neovascularisation due to other causes) or co-existence of other retinal disease in the study eye
- Significant optical media opacities that would result in poor imaging quality on OCT scans in the study eye
- Intraocular surgery in the study eye 3 months before or within 1 month after the treatment switch
Exclusion
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2023
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT06124677
Start Date
November 1 2023
End Date
December 1 2023
Last Update
December 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Miklos Schneider
Glostrup Municipality, Denmark, 2600